GlassScriptPhysician profile
James M Adams
NPI 1184681439
$14,885.70
in general payments reported to CMS, 2019-2025
17 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,353 · 2020: $41.31 · 2021: $23.00 · 2022: $2,616 · 2023: $994 · 2024: $1,368 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $6,905.92 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $3,656.89 | 2019-2025 | Descovy, Yeztugo |
| Theratechnologies INC. | $2,632.67 | 2019-2024 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $445.57 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Scientific Affairs, LLC | $218.26 | 2019-2023 | Symtuza |
| Amgen INC. | $167.75 | 2023-2024 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $165.82 | 2023-2024 | Farxiga, Airsupra |
| Abbvie INC. | $146.26 | 2021-2025 | |
| Thd America, INC. | $112.58 | 2025 | |
| Novo Nordisk INC | $86.58 | 2023-2025 | Rybelsus, Wegovy, Ozempic |
| Janssen Biotech, INC. | $75.68 | 2023 | Symtuza |
| Emd Serono, INC. | $70.88 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.24 | 2023-2024 | Jardiance, Synjardy |
| Pfizer INC. | $50.72 | 2023-2024 | |
| Glaxosmithkline, LLC. | $48.29 | 2024-2025 | Shingrix, Arexvy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.81 | 2023 | Veozah |
| Napo Pharmaceuticals INC | $15.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.